So far, multiple small molecule inhibitors or monoclonal antibodies (mAbs) targeting CD73 have gradually emerged for cancer treatment.[8] Small molecule inhibitors might be more efficient for tissue penetration and tumor retention than mAbs, primarily due to their small molecular weight.[12] This is particularly relevant in the context of pancreatic cancer, where the microenvironment is characterized by dense desmoplasia. This evidence concerns the gene NT5E and familial pancreatic carcinoma.